COVID-19 UPDATE: Under the 14-day quarantine travel advisory announced by the Governors of New Jersey, New York and Connecticut, individuals traveling to or returning from states with increasing rates of COVID-19 are advised to self-quarantine for 14 days. The current list of states, which will be updated regularly, can be found at NY.Gov and NJ.Gov. This includes travel by train, bus, car, plane and any other method of transportation. If you have traveled to one of these states and have stayed longer than 24 hours, we kindly request you self-quarantine at home for 14 days prior to coming into the office. If you would like to schedule a Virtual Appointment, please call 1-855-ENTA-DOC. For more information on how ENTA is taking extra precautions to provide the safest environment possible during the COVID-19 pandemic, please click here.
12/05/2011 in press release
Moshe Ephrat, MD, of ENT and Allergy Associates®, LLP, appears on Dr. Oz Show.
Discusses Sinus Disease and Treatment
Tarrytown, NY – Dr. Moshe Ephrat, an ear, nose and throat specialist practicing in the Lake Success office of ENT and Allergy Associates, LLP (ENTA), will make his first appearance on the popular daytime television program The Dr. Oz Show.
The episode will air Friday, December 16th on Fox 5 at 4:00pm. Dr. Ephrat joins Dr. Oz for a segment on sinus disease and treatment. This follows on the heels of a number of local and regional media appearances by various ENTA physicians.
More than 37 million Americans suffer from at least one episode of acute sinus disease symptoms each year. The number has soared in the last decade, possibly due to increased pollution and increased resistance to antibiotics.
“Among other potential solutions, patients may now benefit from balloon sinus dilation, which enlarges the natural openings in the sinuses by using a small, flexible balloon placed in the nose to reach the sinuses”, commented Dr. Ephrat. “The balloon is gradually inflated to gently restructure the previously blocked nasal passage, restoring normal sinus drainage and function. This approach allows patients to return to normal activities quickly”.
Dr. Ephrat, President of the Long Island Society of Otolaryngology - Head and Neck Surgery, has over 10 years of experience in sinus surgery. He trains surgeons as an Assistant Clinical Professor for the Albert Einstein College of Medicine as well as the Hofstra North Shore - LIJ School of Medicine. He also serves on ENTA’s Electronic Medical Record (EMR) Sub-committee and is the Clinical Director, Advanced Facial Plastics pision.
To better meet the growing needs of its Nassau County patient population, ENTA will soon be expanding its Lake Success office to an impressive 5,085 square feet of state-of-the-art clinical workspace. The Practice is also actively recruiting a laryngologist to add to its Voice and Swallowing Center™ team.
Dr. Moshe Ephrat is joined in Lake Success by three other superb ENTA physicians. Dr. B. Todd Schaeffer-a board certified surgeon who specializes in surgery of the nose, face, neck, sinuses and skull base; Dr. Ron Mitzner, who’s interests are in adult and pediatric ENT, sinus disorders, obstructive sleep apnea, head and neck disease, and disorders of the thyroid/parathyroid; and Dr. Brian Safier, fellowship trained in Adult and Pediatric Allergy and Immunology and also a leader in the field of allergy, asthma and immunology.
Each of ENT and Allergy Associates’ 36 clinical locations provides access to a full complement of services, including General Adult and Pediatric ENT, Voice and Swallowing, Facial Plastics and Reconstructive Surgery, Disorders of the Inner Ear and Dizziness, Asthma, Clinical Immunology, Diagnostic Audiology, Hearing Aid dispensing, Sleep and CT services. Visit www.entandallergy.com for more information. The practice has a clinical alliance with the Mount Sinai Medical Center for the treatment of diseases of the head and neck and a partnership with the American Cancer Society to educate and treat patients with smoking disorders and cancer. The Practice has also expanded its clinical capabilities to include advanced Immunodeficiency trials.